Insider Buying: Athenex Inc (ATNX) Director Buys 10,000 Shares of Stock

Athenex Inc (NASDAQ:ATNX) Director Jinn Wu bought 10,000 shares of the stock in a transaction dated Friday, February 9th. The stock was purchased at an average cost of $13.64 per share, for a total transaction of $136,400.00. Following the acquisition, the director now owns 249,208 shares of the company’s stock, valued at $3,399,197.12. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Athenex Inc (NASDAQ:ATNX) traded down $0.09 during midday trading on Friday, hitting $14.12. 353,645 shares of the company traded hands, compared to its average volume of 372,366. Athenex Inc has a 12-month low of $11.21 and a 12-month high of $20.79. The firm has a market capitalization of $783.52 and a PE ratio of -5.12.

Athenex (NASDAQ:ATNX) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.30) EPS for the quarter. sell-side analysts predict that Athenex Inc will post -2.3 earnings per share for the current year.

Several analysts have recently weighed in on ATNX shares. JPMorgan Chase & Co. started coverage on shares of Athenex in a report on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 target price on the stock. BidaskClub downgraded shares of Athenex from a “hold” rating to a “sell” rating in a report on Thursday, January 4th. Finally, Deutsche Bank set a $20.00 target price on shares of Athenex and gave the company a “buy” rating in a report on Wednesday, January 17th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $27.80.

Several hedge funds and other institutional investors have recently made changes to their positions in ATNX. Bank of New York Mellon Corp acquired a new stake in shares of Athenex in the second quarter valued at about $240,000. Vanguard Group Inc. acquired a new stake in shares of Athenex in the second quarter valued at about $800,000. California Public Employees Retirement System acquired a new stake in shares of Athenex in the second quarter valued at about $800,000. OxFORD Asset Management LLP acquired a new stake in shares of Athenex in the second quarter valued at about $956,000. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Athenex in the second quarter valued at about $320,000. Hedge funds and other institutional investors own 2.69% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insider Buying: Athenex Inc (ATNX) Director Buys 10,000 Shares of Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/09/insider-buying-athenex-inc-atnx-director-buys-10000-shares-of-stock.html.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply